BiotechTube
RootPath Genomics

RootPath Genomics

Cambridge, United States· Est.
rootpath.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

RootPath Genomics is a private, pre-revenue biotechnology company founded in 2018, operating as a platform technology provider in the synthetic biology space. Its proprietary molecular programming-based DNA fragment assembly technology aims to solve key bottlenecks in generating and testing synthetic gene libraries, which is critical for functional genomics and engineered cell therapy development. The company's mission is to enable 'biology at scale' by providing researchers with tools for massively parallel gene function interrogation. RootPath appears to be in a strategic position to partner with large biopharma and biotech companies engaged in cell therapy and target discovery.

OncologyGenetic Diseases

Technology Platform

Proprietary molecular programming-based DNA fragment assembly technology for high-throughput, accurate synthesis of long gene sequences integrated with functional screening capabilities.

Funding History

2
Total raised:$35M
Series A$30M
Seed$5M

Opportunities

The rapid expansion of the cell and gene therapy market creates a massive demand for technologies that can accelerate the design-build-test cycle for genetic constructs.
RootPath's platform is well-positioned to become a critical enabling tool for biopharma R&D, offering opportunities for high-value partnerships and recurring revenue streams.
The technology's applicability also extends into non-therapeutic areas like agricultural biology and industrial enzymes, providing additional market avenues.

Risk Factors

Key risks include intense competition from established DNA synthesis and synthetic biology companies, the technical challenge of consistently delivering on the promise of high-throughput functional data, and the reliance on venture funding and partnership deals for financial sustainability in a capital-intensive sector.
Failure to secure major partnerships could stall growth.

Competitive Landscape

RootPath competes in the synthetic biology and gene synthesis tools market against large players like Twist Bioscience and Ginkgo Bioworks (through its Foundry platform), as well as other specialized startups. Its differentiation hinges on the integrated 'build-and-test' workflow focused specifically on long, complex genes for functional interrogation in cell therapy, a more specialized niche than general oligo or gene synthesis.

More companies in Synthetic Biology →More companies in United States →